The role of excipients in determining the pharmaceutical and therapeutic properties of medicinal agents (Review)

Pharmaceutical Chemistry Journal

Volumn 43, Issue 4, 2009, Pages 230-234

  Aleeva, G N ^a   Zhuravleva, M V ^a   Khafiz'Yanova, R Kh ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Biopharmaceutical classification system; Biowaiver; Excipients; Medicinal formulation; Safety; Toxicity

Indexed keywords

DISINTEGRATING AGENT; EXCIPIENT; GLIDING AGENT; GLUE; HERBACEOUS AGENT; STABILIZING AGENT;

DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; MICROBIOLOGICAL PARAMETERS; REVIEW; STANDARD;

EID: 69249205403     PISSN: 0091150X     EISSN: 15739031     Source Type: Journal    
DOI: 10.1007/s11094-009-0265-4     Document Type: Review

References (52)

1. L. D. Edwards, A. J. Fletcher, A. W. Fox, P. D. Stonier, Principles and Practice of Pharmaceutical Medicine, John Wiley and Sons Ltd., The Atrium, Southern Gate, Chichester,West Sussex PO19 8SQ, England (2007).
2. Drug and Biological Development from Molecule to Product and Beyond, R. P. Evens (Ed.), Springer Science and Business Media, LLC (2007).
3. Federal Law No. 86-FZ, "Medicines," 22 June 1998.
4. Letter from Director of the Federal Health and Social Development Surveillance Service R. U. Khabrief, "Monitoring Excipient Quality," No. 01I-343 / 05.
5. US Pharmacopeia, 28th rev., NF 23, USP Convention, Rockville, MD (2005).
6. I. I. Webster's New College Dictionary, Houghton Mifflin Company, Boston, Massachusetts (1995), p. 39.
7. Guidance for Industry: Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients, US Department of Health and Human Services, Food and Drug Administration (2005).
8. Guidance for Industry: Nonclinical Studies for Development of Pharmaceutical Excipients, US Department of Health and Human Services, Food and Drug Administration (2005).
9. Inactive Ingredient Guide, US Department of Health and Human Services, Food and Drug Administration (2005).
10. T Sam 2000 Drug Info. J. 34 875 894
11. V. I. Chueshov, M. Yu. Chernov, and L. M. Khokhlova, Industrial Drugs Technology [in Russian], MTK-Kniga, Vol. 2 (1999).
12. I. A. Murav'ev, Drugs Technology [in Russian], Meditsina, Moscow (1980), Vol. 1 - 2.
13. SS Rowlands 2001 Drug Info. J. 35 993 1001
14. A. V. Titova, A. P. Arzamastsev, A. I. Luttseva, and N. V. Trius, Proceedings of the XII Russian National Conference "Humans and Medicines" [in Russian], Moscow (2005), pp. 36 - 37.
15. E. R. Montgomery and W. Manu-Tawiah, Am. Pharm. Rev., 34 - 39 (2004).
16. M. Erickson, Am. Pharm. Rev., 88 - 94 (2005).
17. RE Osterberg NA See 2003 Int. J. Tox. 22 377
18. N Tsuchiya S Matsushima N Takasu, et al. 2004 Tox. Path. 32 408 412
19. P. J. Crowley, L. G. Martini, in: J. Swarbrick, J. C. Boylan (Eds.), Encyclopedia of Pharmaceutical Technology, Marcel Dekker, Inc., New York (2002).
20. G Pifferi P Restani 2003 Farmaco 58 541 550
21. A. V. Titova, Author's Abstract of Doctoral Thesis in Pharmaceutical Sciences [in Russian], Moscow (2006).
22. Yu. A. Egoshina, L. A. Potselueva, and T. N. Galiullina, Excipients in Tablet Manufacture [in Russian], KGMU, Kazan' (2006).
23. V. N. Bol'shakov, Excipients in Drug Formulation Technology [in Russian], Leningrad (1991).
24. Handbook of Pharmaceutical Excipients, American Pharmaceutical Association and the Pharmaceutical Society of Great Britain, Washington, D. C. (1986).
25. ME Johnsson M Nicklasson 1986 J. Pharm. Pharmacol. 54 38 54
26. A. Katdare and M. V. Chaubal, Excipient Development for Pharmaceutical, Biotechnology and Drug Delivery Systems, Informa Healthcare USA (2006).
27. L Ochoa M Igartua R Ma, et al. 2005 J. Pharm. Pharm. Sci. 8 2 132 140
28. T Allen P Cullis 2004 Science 303 1818 1822
29. G Vansavage CT Rhodes 1995 Drug Dev. Ind. Pharm. 21 93 118
30. M Kumar N Kumar 2001 Drug Dev. Ind. Pharm. 27 1 30
31. Y. W. Chien, in: Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. C. Boyland (Eds.), Dekker Inc., New York (1990), pp. 281 - 313.
32. V. Kumar and G. S. Banker, Drug Dev. Ind. Pharm., No. 19, 1 - 31 (1993).
33. G. A. Agyilirah and G. S. Banker, in: Polymers for Controlled Drug Delivery, P. J. Tarcha (Ed.), CRC Press, Boca Raton, FL (1991), pp. 39 - 66.
34. G Van Savage CT Rhodes 1995 Drug Dev. Industr. Pharm. 21 1 93
35. J. E. Hogan, G. Cole, in: Pharmaceutical Coating Technology, J. Hogan and M. E. Aulton (Eds.), Taylor and Francis, London (1995).
36. NW Fish JR Bloor 1999 Expert Opin. Ther. Patents 9 1515
37. AW Basit 2000 Pharm. Technol. Eur. 12 2 30
38. DC Monkhouse JL Lach 1972 Can. J. Pharm. Sci. 7 2 29 46
39. MC Gohel 2005 J. Pharm. Pharm. Sci. 8 1 76 93
40. MJ Tobyn GP McCarthy JN Staniforth S Edge 1998 Int. J. Pharm. 169 183 194
41. JK Guillory CH Soon JL Lach 1969 J. Pharm. Sci. 58 3 301 308
42. DF Steele S Edge MJ Tobyn, et al. 2003 Drug Dev. Ind. Pharm. 29 4 475 487
43. SM Blaug W-T Huang 1973 J. Pharm. Sci. 62 4 652 655
44. C Ahlneck G Zografi 1990 Int. J. Pharm. 62 87 95
45. Waiver of in Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Guidance for Industry, CDER / FDA (2000).
46. R Löbenberg GL Amidon 2000 Eur. J. Pharm. Biopharm. 50 5 12
47. DG Fatouros DM Karpf FS Nielsen A Mullertz 2007 Ther. Clin. Risk Manag. 3 4 591 604
48. CJ Porter CW Pouton JF Cuine WN Charman 2008 Adv. Drug Deliv. Rev. 60 6 673 691
49. BJ Boyd SM Khoo DV Whittaker, et al. 2007 Int. J. Pharm. 340 1-2 52 60
50. AH Dantzig DP de Alwis M Burgess 2003 Adv. Drug Deliv. Rev. 55 133 150
51. V. G. Kukes, S. V. Grachev, D. A. Sychev, and G. V. Ramenskaya Drug Metabolism. Scientific Bases of Personalized Medicine [in Russian], Geotar-Media, Moscow (2007).
52. JM Dintaman JA Silverman 1999 Pharm. Res. 16 1550 1556